Content area

Abstract

The isotopic labelling of small molecules is integral to drug development and for understanding biochemical processes. The preparation of carbon-labelled α-amino acids remains difficult and time consuming, with established methods involving label incorporation at an early stage of synthesis. This explains the high cost and scarcity of C-labelled products and presents a major challenge in 11C applications (11C t1/2 = 20 min). Here we report that aldehydes catalyse the isotopic carboxylate exchange of native α-amino acids with *CO2 (* = 14, 13, 11). Proteinogenic α-amino acids and many non-natural variants containing diverse functional groups undergo labelling. The reaction probably proceeds via the trapping of *CO2 by imine-carboxylate intermediates to generate iminomalonates that are prone to monodecarboxylation. Tempering catalyst electrophilicity was key to preventing irreversible aldehyde consumption. The pre-generation of the imine carboxylate intermediate allows for the rapid and late-stage 11C-radiolabelling of α-amino acids in the presence of [11C]CO2.

Carbon-labelled α-amino acids are valuable compounds in drug development and nuclear medicine, but are difficult and time consuming to prepare. Now, an aldehyde-catalysed method has been developed for the direct C1-labelling of α-amino acids using *CO2 (* = 14, 13, 11), providing access to many proteinogenic and non-natural labelled α-amino acids.

Details

Title
Aldehyde-catalysed carboxylate exchange in α-amino acids with isotopically labelled CO2
Author
Bsharat, Odey 1 ; Doyle, Michael G. J. 1   VIAFID ORCID Logo  ; Munch, Maxime 2   VIAFID ORCID Logo  ; Mair, Braeden A. 2   VIAFID ORCID Logo  ; Cooze, Christopher J. C. 1 ; Derdau, Volker 3   VIAFID ORCID Logo  ; Bauer, Armin 3 ; Kong, Duanyang 1 ; Rotstein, Benjamin H. 2   VIAFID ORCID Logo  ; Lundgren, Rylan J. 1   VIAFID ORCID Logo 

 University of Alberta, Department of Chemistry, Edmonton, Canada (GRID:grid.17089.37) 
 University of Ottawa, Department of Biochemistry, Microbiology and Immunology and Department of Chemistry and Biomolecular Sciences, Ottawa, Canada (GRID:grid.28046.38) (ISNI:0000 0001 2182 2255); University of Ottawa Heart Institute, Ottawa, Canada (GRID:grid.28046.38) (ISNI:0000 0001 2182 2255) 
 Sanofi-Aventis Deutschland GmbH, R&D, Integrated Drug Discovery, Isotope Chemistry, Industriepark Höchst, Frankfurt, Germany (GRID:grid.420214.1) 
Pages
1367-1374
Publication year
2022
Publication date
Dec 2022
Publisher
Nature Publishing Group
ISSN
17554330
e-ISSN
17554349
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2755010966
Copyright
© The Author(s), under exclusive licence to Springer Nature Limited 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.